Biomedicine & Pharmacotherapy (Sep 2022)

SPARC in hematologic malignancies and novel technique for hematological disease with its abnormal expression

  • Qing Nian,
  • Jingwei Li,
  • ZhongYu Han,
  • Qi Liang,
  • Maoyu Liu,
  • Chan Yang,
  • Fernando Rodrigues-Lima,
  • Tao Jiang,
  • Liyun Zhao,
  • Jinhao Zeng,
  • Chi Liu,
  • Jianyou Shi

Journal volume & issue
Vol. 153
p. 113519

Abstract

Read online

Secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or BM-40, is a matricellular protein involved in several biological processes including cell adhesion, growth factor availability, extracellular matrix remodeling and immune-regulation. SPARC has also been associated with a variety of diseases including diabetes, colon cancer, and leukemia. The expression of SPARC in different diseases exhibits some degree of ambiguity, especially in hemopathies. Herein, we review the current expression and effects of SPARC in various hematologic disorders with respect to nanoparticle albumin bound innovative therapies and related diagnostic research, providing a clinical perspective on the use of NAB technology in the frontier treatment of hematologic diseases.

Keywords